HOME >> MEDICINE >> NEWS
New rheumatoid arthritis drug developed at UCSD promises improved treatment options

Researchers at the University of California, San Diego (UCSD) School of Medicine have announced successful completion of Phase II clinical trials of a novel drug for the treatment of rheumatoid arthritis (RA), one that works without suppressing the patient's immune system.

Salvatore Albani, M.D., Ph.D, professor of medicine and pediatrics and Director of the Translational Research Unit of the Clinical Investigation Institute (CII) at the UCSD School of Medicine, recently presented a summary of the findings at the "Frontiers of Clinical Investigation Symposium." The symposium, sponsored by the CII and Nature Medicine, was held in La Jolla, California in September.

The new drug, dnaJP1, is a peptide derived from a naturally occurring protein, dnaJ, which generates inflammation in RA patients, whose inflammatory-control mechanisms are impaired. The impairment causes the body's T cells which trigger inflammation to kill and clear foreign pathogens in the body to attack the body's own tissues.

"In essence, we re-educated the immune system T cells to be tolerant of the dnaJP1 amino acid sequence, which would usually contribute to inflammation in rheumatoid arthritis patients," Albani said.

DnaJP1 works by resetting the ability of the patient's immune system to tolerate dnaJ, thus transforming a potentially damaging trigger into a tool for controlling the disease. Oral ingestion of dnaJP1 is key, because the mucosal immune system found in the gut has the ability to "teach" the body to view a protein as one that isn't dangerous or foreign. Much as food is ingested into the body and not rejected, the body tolerates dnaJP1.

Current medications for treating RA range from anti-inflammatory drugs, such as aspirin, to corticosteroids and medicines that alleviate symptoms by suppressing or killing the body's immune response, basically crippling the body's ability to defend itself against other infectious diseases or cancer.


'"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
14-Oct-2005


Page: 1 2 3

Related medicine news :

1. Green tea compound may be a therapy for people with rheumatoid arthritis
2. The link between rheumatoid arthritis and cancer
3. Predicting the risk of rheumatoid arthritis for early arthritis patients
4. Women with rheumatoid arthritis have significantly less chance of remission than men
5. New study reveals postcode lottery for rheumatoid arthritis treatment
6. Cancer drug may be remedy for rheumatoid arthritis, Stanford study finds
7. A new approach to rheumatoid arthritis
8. Increased odds of rheumatoid arthritis in women smokers without genetic risk factor
9. New research addresses taboos around the impact of rheumatoid arthritis on patients sex lives
10. New evidence shows MabThera inhibits joint damage in patients with rheumatoid arthritis
11. PTPN22 gene associated with both susceptibility and disease progression in rheumatoid arthritis

Post Your Comments:
(Date:8/28/2015)... ... August 28, 2015 , ... The Quatela Center for Plastic Surgery is excited ... only nonsurgical product approved by the Food and Drug Administration to eliminate submental fat, ... Dr. William Koenig are among the premier cosmetic surgeons in Rochester to offer ...
(Date:8/28/2015)... ... August 28, 2015 , ... Healthpointe clinics ... to go deep sea diving. The act of recreational diving exposes the ... these reasons, it is vital that all recreational and professional divers undergo regular ...
(Date:8/28/2015)... ... August 28, 2015 , ... United Benefit Advisors ... TJS Insurance Group as its newest Partner Firm. Founded in 1924 and headquartered ... them focused on their goals. Within the past 10 years, TJS Insurance Group ...
(Date:8/28/2015)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... be taken in order to ease the stress on the atmosphere, and lessen the ... understand fully the real cause of global warming and urges them to look into ...
(Date:8/28/2015)... ... 2015 , ... An independent study recently conducted confirms that ... change to treatment recommendations and diagnosis. The 2015 return on investment (ROI) study ... analyzed WorldCare’s second opinion process. , The study reviewed cases across three representative ...
Breaking Medicine News(10 mins):Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Healthpointe Now Offering Scuba Physicals 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:Wake Up and Smell the Sick Atmosphere Says Yisrayl Hawkins in New Article This Week 2Health News:WorldCare International, Inc. Celebrates Findings of Independent ROI Study 2
(Date:8/28/2015)... and PITTSBURGH , Aug. 28, ... today announced that its shareholders have approved Mylan,s ... PRGO ; TASE) and the related issuance of ... extraordinary general meeting of shareholders held today. The ... at the extraordinary general meeting. In addition, the ...
(Date:8/28/2015)... 2015 The global mHealth ... billion by 2020, growing at a CAGR of 47.6% ... by Grand View Research, Inc. Monitoring services is expected ... 2014 to 2020.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ... rising incidences of chronic diseases such as cancer, heart ...
(Date:8/27/2015)... 2015 ieCrowd™ today announced the achievement ... of the company,s supplemental oxygen delivery device, Smart ... developed by ieCrowd,s subsidiary Smart Oxygen Solutions TM ... for oxygen based on level of activity.  The ... the Smart Oxygen device would require a series ...
Breaking Medicine Technology:Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4
Cached News: